2017 ASCO Annual Meeting

Karim Fizazi, MD, PhD, Gustave Roussy Cancer Campus and University Paris-Sud, presenting Abstract LBA3, LATITUDE: A phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in newly diagnosed high-risk metastatic hormone-na?ve prostate cancer (mHNPC) patients (pts), during Saturday Press Briefing

Chicago, IL - 2017 ASCO Annual Meeting - Karim Fizazi, MD, PhD, Gustave Roussy Cancer Campus and University Paris-Sud, presenting Abstract LBA3, LATITUDE: A phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in newly diagnosed high-risk metastatic hormone-na?ve prostate cancer (mHNPC) patients (pts), during Saturday Press Briefing at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Saturday, June 3, 2017. Approximately 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 53rd Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/Michael R. Schmidt 2017 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org